胰腺癌治疗的最新进展
Jorge Paulino1, Hélder Mansinho2
1General Surgery Department. Hospital da Luz. Lisboa. Portugal.
Acta medica portuguesa
|October 3, 2023
概括
胰腺管腺癌 (PDAC) 的生存率正在通过新辅助策略和先进的外科手术技术得到改善. 本综述涵盖了PDAC的最新手术和瘤干预措施,以提高患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 胰腺管腺癌 (PDAC) 是全球和欧洲癌症死亡的主要原因,葡萄牙死亡率上升.
- 带有负边缘的完整手术切除和淋巴切除术是PDAC中长期存活的唯一机会.
- PDAC是一种全身性疾病,在手术后复发率很高,因此全身性治疗至关重要.
研究的目的:
- 审查PDAC手术和瘤管理当前的最先进技术.
- 要突出最近的进展,旨在提高PDAC患者的生存率.
- 讨论新辅助策略和不断发展的外科手术方法的影响.
主要方法:
- 对PDAC最近的手术和瘤干预的文献综述.
- 分析新辅助剂策略及其对生存和切除能力的影响.
- 检查血管切除的进展和对寡头转移性疾病的治疗.
主要成果:
- 与前期手术相比,新辅助药的策略显著提高了整体存活率,特别是在边缘切除PDAC.
- 新辅助疗法促进了下降阶段,使R0切除 (完全切除瘤) 成为可能.
- 最近的外科进展包括更具侵略性的血管切除和在寡头转移性PDAC中的切除.
结论:
- 新辅助策略和先进的外科手术技术正在改变PDAC管理.
- 这些方法提供了更好的生存率和更好的切除可能性.
- 对手术和瘤干预的持续研究对于推进PDAC治疗至关重要.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
108
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
108
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K